Compare JZXN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JZXN | INDP |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.6K | 125.2M |
| IPO Year | 2020 | 2021 |
| Metric | JZXN | INDP |
|---|---|---|
| Price | $1.15 | $2.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 72.7K | ★ 1.5M |
| Earning Date | 02-24-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.92 |
| 52 Week High | $8.50 | $8.57 |
| Indicator | JZXN | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 75.24 |
| Support Level | $1.07 | $2.41 |
| Resistance Level | $1.17 | $3.00 |
| Average True Range (ATR) | 0.08 | 0.23 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 33.33 | 93.75 |
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It is into trade business with a focus on sales of new energy batteries including design, commissioned processing, transportation and packaging, sales of electrical equipment, mobile phone accessories and other products. Its revenues consist of two reportable operating segments: (i) Sales of new energy batteries, including production, transportation, and packaging, in the mainland Pearl River Delta region; and(ii) Sales and production of electric vehicles in Southeast Asia, including two-wheelers, three-wheeled electric scooters, and slow-speed vehicles.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.